Fisher Asset Management LLC Purchases 691,267 Shares of Viridian Therapeutics, Inc. $VRDN

Fisher Asset Management LLC raised its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 135.6% in the third quarter, Holdings Channel reports. The fund owned 1,201,226 shares of the company’s stock after buying an additional 691,267 shares during the quarter. Fisher Asset Management LLC’s holdings in Viridian Therapeutics were worth $25,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Simplify Asset Management Inc. bought a new position in Viridian Therapeutics in the 3rd quarter worth approximately $1,079,000. Corton Capital Inc. acquired a new stake in shares of Viridian Therapeutics in the second quarter worth $248,000. Y Intercept Hong Kong Ltd increased its position in Viridian Therapeutics by 430.3% during the third quarter. Y Intercept Hong Kong Ltd now owns 64,594 shares of the company’s stock worth $1,394,000 after acquiring an additional 52,414 shares during the period. Rice Hall James & Associates LLC raised its stake in Viridian Therapeutics by 65.2% during the 3rd quarter. Rice Hall James & Associates LLC now owns 851,663 shares of the company’s stock valued at $18,379,000 after purchasing an additional 336,040 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in Viridian Therapeutics by 411.8% in the 3rd quarter. SG Americas Securities LLC now owns 62,118 shares of the company’s stock valued at $1,341,000 after purchasing an additional 49,981 shares during the period.

Viridian Therapeutics Price Performance

Viridian Therapeutics stock opened at $29.32 on Wednesday. The business has a 50 day simple moving average of $30.93 and a 200 day simple moving average of $26.68. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.65 and a quick ratio of 12.65. The company has a market capitalization of $3.00 billion, a PE ratio of -8.91 and a beta of 1.00. Viridian Therapeutics, Inc. has a one year low of $9.90 and a one year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.18). The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $15.75 million. Viridian Therapeutics had a negative return on equity of 83.25% and a negative net margin of 483.57%. On average, sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on VRDN shares. Evercore restated an “outperform” rating and set a $44.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 20th. Royal Bank Of Canada decreased their target price on Viridian Therapeutics from $45.00 to $42.00 and set an “outperform” rating on the stock in a research report on Friday, February 27th. Wedbush upped their price target on Viridian Therapeutics from $42.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Wall Street Zen upgraded Viridian Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, BTIG Research restated a “buy” rating and set a $61.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, November 4th. Thirteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Viridian Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $42.43.

Insider Buying and Selling at Viridian Therapeutics

In related news, insider Jennifer Tousignant sold 2,272 shares of the stock in a transaction dated Wednesday, December 31st. The shares were sold at an average price of $31.16, for a total transaction of $70,795.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.65% of the company’s stock.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.